Penn Medicine Provider
Medical Oncology, Hematology
Emily Tomasulo, DO, FACP
5.0
(277)
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Philadelphia College of Osteopathic Medicine
  • Residency: Pennsylvania Hospital
  • Fellowship: National Institutes of Health

What my patients think about me

Average Rating
5.0

277 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
she's very good provider
May 2025
5.0
5.0
excellent care!
May 2025
5.0
5.0
i love my dr
April 2025
5.0
5.0
she was amazing! great bedside manner. explained everything so we understood it. didn't feel hurried. asked questions. answered questions. she's a fabulous doctor!

Insurance accepted

My Locations

Learn about location
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Tomasulo is a Penn Medicine physician.

Qualifications and experience

My research

Christopher Pleyer, Emily Tomasulo, et. al Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia , Blood Supplement: 2024

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael Fradley, and Stephen J. Schuster Resolution of ibrutinib-associated hypertension with transition to alternate covalent BTKi , Blood Supplement: 2024

Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL , Leukemia & Lymphoma, 64(14): 2023

Itsara A, Sun C, Bryer E, et al. Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study , Blood Supplement: 2023

Emily Tomasulo Chronic Lymphocytic Leukemia Chapter , Bethesda Handbook of Hematology: 2023

Bryer E, Itsara A, Ahn I et al. Ibrutinib-associated sudden death in patients with CLL , Blood, 140(Supplement 1): 2022

Bryer EJ, Destefano C, Kazandjian D. Current and prospective antibody-based therapies in multiple myeloma , Semin Oncol, 49(1): 2022,41-47

Bryer EJ, Stein E, Goldberg S. Multivessel Coronary Artery Disease , Mayo Clinic Proceedings: Innovations, Quality, and Outcomes.: 2020

Bryer E, Dew A, Hill E, et al. A phase II pilot study of avelumab in combination with hypofractionated radiotherapy in patients with relapsed refractory multiple myeloma , Blood, 136(Supplement 1): 2020

Bryer EJ, Kallan MJ, Chiu TS. A Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy- Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration. , EJHaem , 1(1): 2020,35-43